Ex-Sarepta execs join new Atlas-backed muscular disease startup fueled by $50M

A new Atlas Venture-founded startup launched Wednesday, backed by $50 million, to develop drugs for a currently untreated form of muscular dystrophy and other muscle-based diseases. Dyne Therapeutics emerged from stealth mode this week with Series A funding from Dutch firm Forbion and Cambridge firms MPM Capital and Atlas. Dyne was founded and incubated by Atlas over the past year. Its first focus area is myotonic dystrophy type 1, a rare genetic disease that causes muscle weakness and affects…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news